首页> 美国卫生研究院文献>OncoTargets and therapy >Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
【2h】

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report

机译:CAR T细胞治疗同种异体造血干细胞移植后急性淋巴细胞白血病髓外复发:1例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Philadelphia chromosome-positive (Ph-positive) acute leukemia (ALL) accounts for around one quarter of adult cases of ALL and is usually associated with poor prognosis. The patients still encounter a high rate of relapse even after they receive hematopoietic stem cell transplantation (HSCT). HSCT is considered the established therapy and best option for many malignant ALL cases, however, disease relapse remains the main reason of failure. In recent years, chimeric antigen receptor (CAR) T-cell therapy has become a promising treatment for patients with advanced blood cancers. Here, we report a rare case of a Ph-positive ALL patient with extramedullary relapse in her cervix after receiving allogeneic HSCT. Given the unsatisfactory response to chemotherapy, tyrosine kinase inhibitor (TKI) treatment, and HSCT transplantation, she had received CD19+ CAR T-cell therapy 8 months earlier. The following ultrasound check indicated that her cervix relapse went through significant remission with almost undetectable tumor mass. This case strongly supports the efficacy of CAR T-cell therapy on adult ALL with extramedullary relapse.
机译:费城染色体阳性(Ph阳性)急性白血病(ALL)约占成人ALL病例的四分之一,通常与预后不良有关。即使接受造血干细胞移植(HSCT),患者仍会出现较高的复发率。 HSCT被认为是许多恶性ALL病例的既定疗法和最佳选择,但是,疾病复发仍然是失败的主要原因。近年来,嵌合抗原受体(CAR)T细胞疗法已成为晚期血液癌患者的有前途的治疗方法。在这里,我们报道了接受异体造血干细胞移植后,子宫颈髓外复发的Ph阳性ALL患者的罕见病例。鉴于对化疗,酪氨酸激酶抑制剂(TKI)治疗和HSCT移植的反应不理想,她在8个月前接受了CD19 + CAR T细胞疗法。随后的超声检查表明她的子宫颈复发经历了明显的缓解,几乎没有发现肿瘤块。该病例强烈支持CAR T细胞疗法对髓外复发的成人ALL的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号